- Caspase Inhibition Suppresses Production of Biologically Active Microparticles in Murine Model of Alcoholic Liver Disease - - Emricasan Improves Survival and Portal Hypertension in Murine Model of Liver Failure - SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the presentation of two posters, both addressing preclinical results with the company's pan-caspase inhibitors, at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015. Poster #1315, "Alcohol stimulates macrophage activation through caspase dependent, hepatocyte derived release of...
↧